Researchers report early clinical results from an experimental optogenetic therapy for people with certain inherited forms of blindness. In a study published in the New England Journal of Medicine, a team led by the University of Pittsburgh School of Medicine and international collaborators administers the treatment to 10 patients and uses a specially designed visual stimulation device. Across the study, some participants show improvements in aspects of visual function.

The approach relies on optogenetics, which uses light to control the activity of specific cells. Coverage from multiple outlets describes optogenetic methods as turning nerve cells on and off with light, potentially enabling cells that normally relay signals to the brain to respond to illumination. While outlets agree the therapy appears safe and may restore only limited sight, they emphasize different framing—some focus on the gene-therapy component and safety, while others highlight how the technique works and the level of vision improvement observed so far.